Not currently recruiting at UCLA
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Summary
- Eligibility
- for people ages 18-75 (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedstudy ends around
- Principal Investigator
- by Steven C. Tsai, MD, PhD

Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Steven C. Tsai, MD, PhD
HS Assistant Clinical Professor, Medicine
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Priothera SAS
- Links
- Sign up for this study
- ID
- NCT05429632
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 366 study participants
- Last Updated